Nabla Bio is an autoverse platform of proprietary biologically informed machine learning that co-develops antibody drugs.
Nabla Bio has raised $26.0M in total funding. The most recent round was Series A. The last funding was announced in May 2024.
Nabla Bio's investors include National Science Foundation, Y Combinator, Khosla Ventures, Radical Ventures, Pillar VC.
Nabla Bio is headquartered in Cambridge, United States.
Nabla Bio is an autoverse platform of proprietary biologically informed machine learning that co-develops antibody drugs.
Nabla Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nabla Bio — Funding & Investors." VCBacked, May 14, 2024, https://www.vcbacked.co/company/nabla-bio. Accessed July 19, 2026.
VCBacked. (2024). Nabla Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/nabla-bio
{{cite web |title=Nabla Bio — Funding & Investors |url=https://www.vcbacked.co/company/nabla-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated